Takeda Pharmaceutical (TAK) Research & Development (2017 - 2026)

Takeda Pharmaceutical has reported Research & Development for 10 years, with the latest figure at -$1.1 billion in Q2 2026.

• On a quarterly basis, Research & Development fell 5.61% year-over-year to -$1.1 billion in Q2 2026; TTM through Jun 2026 was -$4.5 billion, a 3.75% increase from a year earlier, with the FY2026 full-year figure at -$4.3 billion, up 10.09% from the prior year.
• Research & Development was -$1.1 billion for Q2 2026 at Takeda Pharmaceutical, up from -$1.2 billion in the prior quarter.
• The five-year high for Research & Development was -$994.4 million in Q2 2025, with the low at -$1.4 billion in Q1 2025.
• Average Research & Development over 5 years is -$1.2 billion, with a median of -$1.2 billion recorded in 2023.
• The sharpest annual moves came in 2022 and 2026: Research & Development slipped 15.45% in 2022, then grew 12.03% in 2026.
• Over 5 years, Research & Development stood at -$1.2 billion in 2022, then dropped by 2.56% to -$1.3 billion in 2023, then gained by 11.69% to -$1.1 billion in 2024, then retreated by 1.71% to -$1.1 billion in 2025, then gained by 7.76% to -$1.1 billion in 2026.
• The last three Research & Development figures came in at -$1.1 billion (Q2 2026), -$1.2 billion (Q1 2026), and -$1.1 billion (Q4 2025), per Business Quant data.